Revvity price target lowered to $110 from $140 at Barclays

Barclays lowered the firm’s price target on Revvity (RVTY) to $110 from $140 and keeps an Overweight rating on the shares as part of a Q1 earnings preview for life science tools and diagnostics group. Tools are still defensive, but less so than in the past given the threat of the pharma-specific tariffs potentially causing another round of budget cuts, the analyst tells investors in a research note. Barclays also downgraded the contract research organizations on lower visibility.